These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 24577126)

  • 1. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
    Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
    Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
    Horey A; Mergenhagen KA; Mattappallil A
    Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
    Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
    Matson KL; Shaffer CL; Beck GL; Simonsen KA
    Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
    Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
    Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
    Cies JJ; Shankar V
    Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
    Hirai T; Hanada K; Kanno A; Akashi M; Itoh T
    Eur J Clin Pharmacol; 2019 Jun; 75(6):859-866. PubMed ID: 30770940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
    Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
    Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy.
    Suzuki Y; Tokimatsu I; Morinaga Y; Sato Y; Takano K; Kohno K; Ogata M; Hiramatsu K; Itoh H; Kadota J
    Clin Chim Acta; 2015 Feb; 440():183-7. PubMed ID: 25476135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
    Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
    Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
    Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
    Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Whole Price of Vancomycin: Toxicities, Troughs, and Time.
    Jeffres MN
    Drugs; 2017 Jul; 77(11):1143-1154. PubMed ID: 28573434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.
    Pritchard L; Baker C; Leggett J; Sehdev P; Brown A; Bayley KB
    Am J Med; 2010 Dec; 123(12):1143-9. PubMed ID: 21183005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
    Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of risk factors for vancomycin-induced nephrotoxicity.
    Park SJ; Lim NR; Park HJ; Yang JW; Kim MJ; Kim K; In YW; Lee YM
    Int J Clin Pharm; 2018 Oct; 40(5):1328-1334. PubMed ID: 29744794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.